Providence licenses mRNA technology to China’s Everest in $100-million deal

Calgary-based Providence Therapeutics struck a $100-million deal with China’s Everest Medicines Ltd. Monday that will see its technology licensed to the Shanghai-based firm to make and sell its mRNA vaccine candidates in emerging markets in Asia including China and Pakistan. Read More